E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Obstructive Pulmonary Disease (COPD) |
|
E.1.1.1 | Medical condition in easily understood language |
COPD is a chronic condition of the lungs which causes people to suffer symptoms such as shortness of breath and coughing. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the superiority of inhaled NVA237 (50 μg od via SDDPI) compared with placebo when added on to a fixed-dose combination of salmeterol/fluticasone propionate (50/500 μg bid via MDDPI), in terms of trough FEV1 after 12 weeks of treatment in the study population.
Trough FEV1 is defined as the mean of the FEV1 measurements taken at 23 hours 15 minutes and 23 hours 45 minutes after the previous morning dose. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the superiority of inhaled NVA237 (50 μg od via SDDPI) compared with placebo, when added on to a fixed-dose combination of salmeterol/fluticasone propionate (50/500 μg bid via MDDPI), in terms of change in total score of St George’s Respiratory Questionnaire for COPD patients (SGRQ-C), after 26 weeks of treatment in the study population.
Other secondary objectives :
To evaluate the effect of inhaled NVA237 (50 μg od via SDDPI) versus placebo added on to fixed-dose combination of salmeterol/fluticasone propionate (50/500 μg bid via MDDPI) in terms of:
• Trough FEV1 at Week 4 and 26
• Total score of the Transition Dyspnea Index (TDI) at Weeks 12 and 26
• Assessment of safety and tolerability |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Current or ex-smokers who have a smoking history of at least 10 pack years (e.g., 10 pack years = 1 pack/day × 10 years, ½ pack/day × 20 years, etc.).
• COPD patients with moderate to severe airflow limitation (Spirometry classification: GOLD 2 or 3) at Visit 2:
- Post-bronchodilator FEV1 ≥30% and <60% of the predicted normal, and,
- Post-bronchodilator FEV1/forced vital capacity (FVC) <0.70
• Patients on maintenance treatment with fixed-dose combination of inhaled salmeterol and fluticasone propionate (50/500 µg) b.i.d. delivered via a proprietary MDDPI device for at least 30 days prior to screening visit (Visit 1).
• Patients in category Gold B or D with a CAT total score ≥10 at screening (Visit 1) and before randomization (Visit 3).
• Patients with a history of at least 1 moderate or severe COPD exacerbation within the previous year.
Other protocol-defined inclusion criteria may apply |
|
E.4 | Principal exclusion criteria |
• Pregnant or nursing (lactating) women
• Women of child-bearing potential, unless they are using effective methods of contraception during the study
• Patients with a history of long QT syndrome or whose QTc measured at run-in (Visit 2) (Fridericia method) is prolonged (>450 ms). (These patients cannot be re-screened.)
• Patients with evidence (upon visual inspection) of oropharyngeal candidiasis at baseline with or without treatment.
• Patients who have not achieved an acceptable spirometry result at run-in (Visit 2) in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria for acceptability and repeatability.
• Patients who have had a COPD exacerbation that required treatment with antibiotics or oral corticosteroids or hospitalization in the 6 weeks prior to screening (Visit 1).
• Patients who have had a respiratory tract infection within 4 weeks prior to screening (Visit 1).
• Patients requiring long term oxygen therapy prescribed for >12 hours per day.
• Patients with allergic rhinitis who use an H1 antagonist or intra-nasal corticosteroids intermittently. (Treatment with a stable dose or regimen is permitted.)
• Patients with concomitant pulmonary disease (e.g., lung fibrosis, sarcoidosis, interstitial lung disease, or pulmonary hypertension), clinically significant bronchiectasis, or history of pulmonary lobectomy, lung volume reduction surgery, or lung transplantation.
• Patients with active pulmonary tuberculosis, unless confirmed by imaging to be no longer active.
Other protocol-defined exclusion criteria may apply |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Timeframe: after 12 weeks of treatment |
|
E.5.2 | Secondary end point(s) |
1. Change in total score of St George’s Respiratory Questionnaire for COPD patients (SGRQ-C).
2. Trough FEV1
3. Total score of the Transition Dyspnea Index (TDI)
4. Assessment of safety and tolerability
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Timeframe: 26 weeks
2. Timeframe: week 4 , week 26
3. Timeframe: week 12 and week 26
4. Timeframe: 26 weeks
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 138 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Austria |
Brazil |
Chile |
Colombia |
Czech Republic |
Egypt |
Germany |
Guatemala |
Hungary |
India |
Italy |
Malaysia |
Mexico |
Peru |
Philippines |
Poland |
Portugal |
Romania |
Russian Federation |
Singapore |
Slovakia |
Spain |
Taiwan |
Thailand |
Tunisia |
Turkey |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 7 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 7 |